Does the media prefer LKFT or RYTM?

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 6 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.61 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakefront Biotherapeutics American Depositary Shares 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$28.35 +0.03 (+0.11%)

As of 05/29/2026 04:00 PM Eastern

Compare

LKFT vs. KYMR, PTGX, LNTH, TGTX, and RYTM

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? MarketBeat compares Lakefront Biotherapeutics American Depositary Shares with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakefront Biotherapeutics American Depositary Shares include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Lantheus (LNTH), TG Therapeutics (TGTX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Kymera Therapeutics had 3 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.61 beat Kymera Therapeutics' score of 0.33 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics presently has a consensus price target of $118.10, indicating a potential upside of 45.04%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, indicating a potential upside of 28.75%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kymera Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Kymera Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	130.11	-$311.35M	-$3.57	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.79	$363.05M	-$1.41	N/A

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	86.45	-$130.15M	-$1.81	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.79	$363.05M	-$1.41	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Lakefront Biotherapeutics American Depositary Shares and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.01 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.61 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Protagonist Therapeutics currently has a consensus target price of $115.21, suggesting a potential upside of 15.72%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, suggesting a potential upside of 28.75%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Protagonist Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats Protagonist Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Lantheus?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, suggesting a potential upside of 28.75%. Lantheus has a consensus target price of $101.86, suggesting a potential upside of 2.58%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, equities analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has a net margin of 18.05% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher earnings, but lower revenue than Lantheus. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.79	$363.05M	-$1.41	N/A
Lantheus	$1.54B	4.19	$233.56M	$4.15	23.93

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 2 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Lakefront Biotherapeutics American Depositary Shares and 4 mentions for Lantheus. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.61 beat Lantheus' score of 0.50 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantheus beats Lakefront Biotherapeutics American Depositary Shares on 10 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to TG Therapeutics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 10.6% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TG Therapeutics has a net margin of 65.95% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has lower revenue, but higher earnings than Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.79	$363.05M	-$1.41	N/A
TG Therapeutics	$700.35M	8.29	$447.18M	$2.86	13.27

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $36.50, suggesting a potential upside of 28.75%. TG Therapeutics has a consensus price target of $52.50, suggesting a potential upside of 38.38%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, TG Therapeutics had 5 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 11 mentions for TG Therapeutics and 6 mentions for Lakefront Biotherapeutics American Depositary Shares. TG Therapeutics' average media sentiment score of 0.70 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.61 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 15 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.79	$363.05M	-$1.41	N/A
Rhythm Pharmaceuticals	$217.17M	27.87	-$196.54M	-$3.13	N/A

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $36.50, indicating a potential upside of 28.75%. Rhythm Pharmaceuticals has a consensus target price of $131.81, indicating a potential upside of 49.24%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 6 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.61 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Rhythm Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.87B	$3.40B	$6.46B	$12.62B
Dividend Yield	N/A	2.28%	2.69%	5.24%
P/E Ratio	-20.11	18.88	21.31	26.28
Price / Sales	1.79	194.68	531.24	94.75
Price / Cash	39.00	124.68	43.65	57.38
Price / Book	0.49	7.27	10.60	7.32
Net Income	$363.05M	$24.20M	$3.56B	$337.27M
7 Day Performance	3.13%	4.11%	2.83%	3.58%
1 Month Performance	1.87%	6.66%	4.57%	5.71%
1 Year Performance	-2.31%	66.32%	37.66%	39.74%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	2.4266 of 5 stars	$28.35 +0.1%	$36.50 +28.7%	-2.5%	$1.87B	$1.04B	N/A	1,310	Analyst Forecast
KYMR Kymera Therapeutics	2.4117 of 5 stars	$78.23 -1.8%	$118.10 +51.0%	+169.2%	$6.44B	$39.21M	N/A	170	Insider Trade
PTGX Protagonist Therapeutics	2.2679 of 5 stars	$98.06 -2.7%	$113.69 +15.9%	+109.2%	$6.31B	$46.02M	N/A	120	Gap Up
LNTH Lantheus	2.212 of 5 stars	$94.66 +1.6%	$99.71 +5.3%	+31.5%	$6.16B	$1.54B	22.81	1,193	Analyst Forecast
TGTX TG Therapeutics	3.882 of 5 stars	$39.40 -0.2%	$52.50 +33.2%	+6.2%	$6.03B	$616.29M	13.78	290	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 5/30/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. KYMR, PTGX, LNTH, TGTX, and RYTM

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Lantheus?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to TG Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. KYMR, PTGX, LNTH, TGTX, and RYTM

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Do insiders & institutionals hold more shares of KYMR or LKFT?

Does the media favor KYMR or LKFT?

Do analysts recommend KYMR or LKFT?

Which has more risk & volatility, KYMR or LKFT?

Which has better valuation and earnings, KYMR or LKFT?

Is KYMR or LKFT more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Which has preferable earnings & valuation, PTGX or LKFT?

Does the media favor PTGX or LKFT?

Do institutionals and insiders hold more shares of PTGX or LKFT?

Do analysts rate PTGX or LKFT?

Which has more risk and volatility, PTGX or LKFT?

Is PTGX or LKFT more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Lantheus?

Do analysts rate LKFT or LNTH?

Is LKFT or LNTH more profitable?

Do insiders & institutionals hold more shares of LKFT or LNTH?

Which has better earnings and valuation, LKFT or LNTH?

Which has more volatility & risk, LKFT or LNTH?

Does the media refer more to LKFT or LNTH?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to TG Therapeutics?

Which has more volatility and risk, LKFT or TGTX?

Do institutionals & insiders have more ownership in LKFT or TGTX?

Is LKFT or TGTX more profitable?

Which has higher valuation & earnings, LKFT or TGTX?

Do analysts recommend LKFT or TGTX?

Does the media prefer LKFT or TGTX?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Which has preferable valuation and earnings, LKFT or RYTM?

Do analysts prefer LKFT or RYTM?

Do institutionals and insiders have more ownership in LKFT or RYTM?

Is LKFT or RYTM more profitable?

Does the media prefer LKFT or RYTM?

Which has more risk & volatility, LKFT or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools